• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Final results of CA180-372/COG AALL1122 phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly-diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (PH plus ALL)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Hunger, S.
    Saha, Vaskar
    Devidas, M.
    Valsecchi, M.
    Gastier-Foster, J.
    Cazzaniga, G.
    Reshmi, S.
    Borowitz, M.
    Moorman, A.
    Heerema, N.
    Carroll, A.
    Swanink, R.
    Martin, P.
    Loh, M.
    Raetz, E.
    Schultz, K.
    Slayton, W.
    Schrappe, M.
    Silverman, L.
    Biondi, A.
    Show allShow less
    Affiliation
    Children’s hospital of Philadelphia, Pediatric Oncology, Philadelphia, United States of America
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background and Aims: We administered EsPhALL chemotherapy plus dasatinib 60 mg/m 2 (starting day 15) at COG (North America and Aus- tralia) and EsPhALL (Italy and UK) sites. Patients (>1-17.99 years) with MRD 0.05% following induction Ib or MRD-positive follow- ing three additional high-risk (HR) chemotherapy blocks were allo- cated to CR1 HSCT. The remaining patients received chemother- apy plus dasatinib for 2 years. Only CNS3 patients received cranial irradiation. Methods: Enrollment was 109 patients (3/2012-5/2014); 3 were ineli- gible and received no trial therapy. Results: All 106 treated-patients achieved CR. With database lock 6/29/19, 48/106 had events including 38 relapses (24 marrow, 4 CNS, 4 marrow+CNS, 4 other, 2 marrow+other), 9 treatment-related deaths (7 in chemotherapy-assigned patients, 2 post-HSCT), and one malignancy. Nineteen (17.9%) patients met HSCT criteria, 15 (14.2%) received CR1 HSCT with 9 remaining event-free, 2 transplant-related deaths (6 weeks, 7 months), and 4 relapses (3 alive, 1 died). Among the four not transplanted, 2 were event-free, 1 relapsed and died, and 1 had an astrocytoma. The remaining 87 patients were assigned to chemotherapy plus dasatinib, with 47 remaining event-free. Seven died in CR1, 5 on-therapy (3 in HR3, 1 reinduction 2, 1 continuation) and 2 post-therapy (21 and 31 months). Thirty-three relapsed, 3 on-therapy at 16-23 months (all alive) and 30 post-therapy (18 12 months, 12 >12 months; 22 alive and 8 deceased). The primary toxicities were febrile neutropenia and infection; one chemotherapy patient discon- tinued dasatinib (allergy) and one discontinued post-HSCT (myelosup- pression). Conclusions: Dasatinib plus EsPhALL chemotherapy is safe and effec- tive in pediatric Ph +ALL. With only 14% of patients undergoing CR1 HSCT, as compared to 81% in the EsPhALL 2004 and 38% in the EsPhALL2010 imatinib trials, this trial demonstrates similar outcomes with 5-year EFS 54.6% (95% CI, 44.5-63.6) and OS 81.7% (95% CI, 82.8-87.9) versus 60.3%/71.5% in EsPhALL 2004, and 57%/71.8% in EsPhALL 2010
    Citation
    Hunger S, Saha V, Devidas M, Valsecchi M, Gastier-Foster J, Cazzaniga G, et al. Final results of CA180-372/COG AALL1122 phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly-diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (PH plus ALL). Pediatric Blood & Cancer. 2020;67:S15-S6
    Journal
    Pediatric Blood & Cancer
    URI
    http://hdl.handle.net/10541/623615
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Paterson Institute for Cancer Research

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.